BioCentury
ARTICLE | Clinical News

ATB-346: Phase II data

August 15, 2016 7:00 AM UTC

An open-label, Canadian Phase II trial in 12 patients with OA of the knee showed that once-daily 250 mg oral ATB-346 reduced Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain...